Takeda Pharmaceutical (NYSE:TAK) Sees Strong Trading Volume – Still a Buy?

Takeda Pharmaceutical Company Limited (NYSE:TAK) saw an uptick in trading volume on Wednesday . 853,714 shares traded hands during mid-day trading, a decline of 47% from the previous session’s volume of 1,609,208 shares.The stock last traded at $13.23 and had previously closed at $13.35.

Takeda Pharmaceutical Trading Down 2.0 %

The stock has a market capitalization of $41.27 billion, a PE ratio of 22.36, a PEG ratio of 0.25 and a beta of 0.51. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average is $13.48 and its two-hundred day moving average is $13.88.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its position in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after acquiring an additional 859 shares during the last quarter. Hexagon Capital Partners LLC raised its holdings in shares of Takeda Pharmaceutical by 34.3% in the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after buying an additional 1,129 shares during the last quarter. Gold Investment Management Ltd. raised its holdings in shares of Takeda Pharmaceutical by 2.0% in the third quarter. Gold Investment Management Ltd. now owns 73,204 shares of the company’s stock valued at $1,049,000 after buying an additional 1,428 shares during the last quarter. Smithfield Trust Co raised its holdings in shares of Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after buying an additional 1,490 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC raised its holdings in shares of Takeda Pharmaceutical by 5.7% in the second quarter. Beverly Hills Private Wealth LLC now owns 30,146 shares of the company’s stock valued at $390,000 after buying an additional 1,625 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.